Approval · Notice of Compliance 2044 · 1999
MIACALCIN: Notice of Compliance 2044
Issued September 1, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2044
- Date
- September 1, 1999
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- For the treatment of post menopausal osteoporosis in females greater than five years postmenopause with low bone mass (for patients who refuse or cannot tolerate treatment with estrogens or in whom estrogens are contraindicated)
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MIACALCIN | 02240775 | Cancelled Post Market |
Medicinal ingredients
- CALCITONIN (SALMON SYNTHETIC) 200 UNIT per SPR